Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …

Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …

Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …